• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Hong Kong·Financial Services·8340.HK
Share

Zijing International Financial Holdings Limited Stocks

HK$ 1.08Last Updated 23.10.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

HK$ 12.44M

HK$ 1.08
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Zijing International Financial Holdings Limited, an investment holding company based in Hong Kong, delivers a broad spectrum of financial services. The firm's offerings include guiding companies through Initial Public Offerings (IPOs) on both the Main Board and GEM Board of The Stock Exchange of Hong Kong Limited, as well as managing the underwriting and distribution of these shares. Its corporate finance advisory capabilities encompass mergers and acquisitions (M&A), corporate restructuring, arranging syndicated loans, and facilitating the issuance of convertible bonds. Zijing also specializes in corporate fundraising, providing strategic advice on structuring financing across equity and debt capital markets, and assisting private companies with pre-IPO private placements. Furthermore, the company advises clients on diverse capital market transactions, such as share placements, rights issues, warrant issuances, share splits, consolidations, privatizations, schemes of arrangement, capital restructurings, convertible bond issuances, and the formation of strategic partnerships. It serves as both a financial advisor and an independent financial advisor for transactions governed by takeovers codes, connected transactions, and notifiable transactions. Zijing also acts as a financial advisor for corporate M&A activities, as well as asset and business acquisitions or disposals for both listed and unlisted entities. Established in 2008, the company was formerly known as Vinco Financial Group Limited until its rebranding to Zijing International Financial Holdings Limited in July 2022. Its headquarters are located in Admiralty, Hong Kong.

Company Valuation

Overvalued
2/7

Based on key historical and expected multiples, the stock is overvalued relative to its peers. Specifically, the stock is overpriced on P/FCF.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

24.10.2026 16:01

Highlights in Small-Cap Stocks: The Merck Deal, the Success of a Hair Loss Pill, and Braze's "Wow Factor"

24.10.2026 13:01

AI investors are already on the brink, a “French kiss” for the euro, and hackers at the gates

24.10.2026 05:04

Hedge funds have ramped up their bets against the euro to a 2020 high

24.10.2026 04:46

France Avoided a Downgrade by Moody’s After a Week of Crisis

24.10.2026 04:37

A key Novartis drug failed to meet expectations. The stock price fell

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026